As of Feb 17
| -0.61 / -1.70%|
The 25 analysts offering 12-month price forecasts for Teva Pharmaceutical have a median target of 42.00, with a high estimate of 80.00 and a low estimate of 27.00. The median estimate represents a +19.32% increase from the last price of 35.20.
The current consensus among 30 polled investment analysts is to Buy stock in Teva Pharmaceutical. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.